VVOS Vivos Therapeutics Inc.

Medical Device Company
1.42
-0.01  -1%
Previous Close 1.43
Open 1.48
52 Week Low 1.18
52 Week High 7.09
Market Cap $32,677,209
Shares 23,012,119
Float 18,415,748
Enterprise Value $17,056,208
Volume 54,196
Av. Daily Volume 83,117
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. First Quarter Appliance Revenue Increased 19% Year-Over-Year

    Management to Host Conference Call Today at 5:00 pm ET

    HIGHLANDS RANCH, Colo., May 16, 2022 (GLOBE NEWSWIRE) --  Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today reported financial results and operating highlights for the first quarter ended March 31, 2022.

    Financial and Operating Highlights

    • Revenue was $3.5 million for the first quarter of 2022, compared to $3.4 million for the first quarter of 2021;

    • Appliance…
    View Full Article
  2. Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29%

    Management to Host Conference Call Today at 5:00 pm ET

    HIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2021.

    Financial and Operating Highlights

    • Revenue increased 33% to $4.4 million for the fourth quarter…
    View Full Article
View All Vivos Therapeutics Inc. News